Chavant Capital Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination in the advanced manufacturing and advanced materials technology sectors. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
SC 13G/A - MOBIX LABS, INC (0001855467) (Subject)
SC 13D - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13D - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
NT 10-Q - MOBIX LABS, INC (0001855467) (Filer)
424B3 - MOBIX LABS, INC (0001855467) (Filer)
8-K - MOBIX LABS, INC (0001855467) (Filer)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
25-NSE - Chavant Capital Acquisition Corp. (0001855467) (Subject)
425 - Chavant Capital Acquisition Corp. (0001855467) (Subject)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
425 - Chavant Capital Acquisition Corp. (0001855467) (Subject)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
IRVINE, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, today announced that its previously announced business combination with Chavant Capital Acquisition Corp. ("Chavant") (NASDAQ:CLAY) has closed, resulting in Mobix Labs becoming a publicly traded company. The business combination and all other proposals presented were approved at an extraordinary general meeting of Chavant shareholders held on December 18, 2023. In connection with the completion of the business combination,
IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly traded special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the Registration Statement on Form S-4 (as amended, the "Registration Statement") filed by Chavant and relating to the previously announced proposed business combination between Mobix Labs and Chavant (the "Bus
IRVINE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), an innovative provider of next generation wireless mmWave 5G and connectivity solutions, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly-traded special purpose acquisition company, announced today the filing by Chavant with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form S-4 (the "Registration Statement") on April 7, 2023, relating to the previously announced proposed business combination of Chavant and Mobix Labs. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previousl
James Peterson, former Chairman, CEO and President of Microsemi Corporation, to serve as Executive Chairman of the Board of the combined company, Mobix Labs, Inc. ("Mobix Labs"); leading a team experienced in growing technology companies organically and accelerating growth with M&A Mobix Labs equity holders will roll 100% of their existing equity holdings into the combined company Transaction values combined company at an implied pro forma enterprise value of approximately $276 million and an implied pro forma equity value of approximately $295 million Transaction includes $30 million fully committed common stock PIPE at $10.00 per share In addition, Mobix Labs has signed a non-binding t
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer. Lantheus Holdings shares dipped 22.5% to $58.93 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Invivyd, Inc. (NASDAQ:IVVD) shares surged 170% to $4.40 after the company reported positive initial results from ongoing CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the Prevention of COVID-19. Cuentas Inc. (NASDAQ:CUEN) shares climbed 71.6% to $2.37. iCoreConnect Inc. (NASDAQ:ICCT) shares jumped 49.4% t
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals aged 9 years and older. Arcutis Biotherapeutics shares gained 25.3% to $3.06 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Banzai International, Inc. (NASDAQ:BNZI) shares gained 120.8% to $13.60 in pre-market trading. The company completed business combination with 7GC & Co on Friday. Royalty Management Holding Corporation (NASDAQ:RMCO) gained 39.8% to $3.51 in pre-market trading after falling around 20% on Friday. Wheeler Real Estate Inv
Shares of Getaround, Inc. (NYSE:GETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results. Getaround posted a quarterly loss of 29 cents per share, versus a year-ago loss of $1.3 per share. The company’s sales came in at $23.80 million, up from $16.74 million in the year-earlier quarter. Getaround shares jumped 86.1% to $0.3071 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Brilliant Acquisition Corporation (NASDAQ:BRLI) shares gained 71.8% to $11.00 in pre-market trading. Near Intelligence, Inc. (NASDAQ:NIR) gained 36.4% to $0.1006 in pre-market trading after gaining ove
Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly traded special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the Registration Statement on Form S-4 (as amended, the "Registration Statement") filed by Chavant and relating to the previously announced proposed business combination between Mobix Labs and Chavant (the "Business Combination"). The extraordinary general meeti